Recombinant SARS-CoV-2 Vaccine(Gazo Biotech/Liaoning Maokangyuan Biotechnology)

重组新冠疫苗（中逸安科/辽宁茂康源）

Report date: 2024/11/23 20:00:08

Base Information

Drug NameRecombinant SARS-CoV-2 Vaccine(Gazo Biotech/Liaoning Maokangyuan Biotechnology)
Drug Alias NameCOVID-2019 vaccine(Gazo Biotech/Liaoning Maokangyuan Biotechnology)
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesGazo Biotech Co LtdLiaoning Maokangyuan Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLiaoning Maokangyuan Biotechnology Co LtdGazo Biotech Co Ltd
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A